US2018064805A1PendingUtilityA1

Method of Vaccination Comprising a Histone Deacetylase Inhibitor

50
Assignee: TURNSTONE LPPriority: Mar 11, 2011Filed: Oct 16, 2017Published: Mar 8, 2018
Est. expiryMar 11, 2031(~4.7 yrs left)· nominal 20-yr term from priority
Inventors:Byram BridleBrian LichtyYonghong WanJean-Simon DialloChantal LemayJohn Bell
A61K 39/29C12N 2760/20243A61K 38/164A61K 39/205A61K 31/167A61K 39/02C12N 2710/10343A61K 38/15A61K 31/165A61P 43/00A61K 45/06A61K 31/18A61K 35/766A61K 39/17A61K 31/4045A61K 2039/545A61K 31/713A61K 39/04A61K 39/285A61K 31/19A61P 31/04A61K 31/4745A61K 39/12A61P 31/06A61P 37/04C12N 2760/20232A61K 38/12A61K 39/165A61K 31/4406A61P 31/12A61P 31/18A61K 31/506A61P 31/22A61P 35/00A61K 31/192A61K 39/0011A61K 39/001188A61K 39/001191A61K 39/001186A61K 39/001181A61K 39/001182A61K 39/001106A61K 39/001192
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A vaccination method comprising administering to a mammal a histone deacetylase inhibitor and a vaccine that delivers an antigen to which the mammal has a pre-existing immunity. 
     
     
         2 . The method of  claim 1 , wherein the antigen is selected from the group consisting of include tumour antigens, antigens from viral pathogens and antigens from bacterial pathogens. 
     
     
         3 . The method of  claim 2 , wherein the tumour antigen is selected from the group consisting of alphafetoprotein (AFP), carcinoembryonic antigen (CEA), CA 125, Her2, dopachrome tautomerase (DCT), GP100, MART1, MAGE protein, NY-ESO1, HPV E6 and HPV E7. 
     
     
         4 . The method of  claim 1 , wherein the antigen is from a pathogenic organism selected from the group consisting of HIV, HepC, FIV, LCMV, Ebola virus and  mycobacterium tuberculosis.    
     
     
         5 . The method of  claim 1 , wherein the histone deacetylase inhibitor is selected from the group consisting of hydroxamic, benzamides, cyclic tetrapeptides, depsipeptides, electrophilic ketones, and aliphatic acid compounds. 
     
     
         6 . The method of  claim 5 , wherein the hydroxamic acids are selected from vorinostat (SAHA), belinostat (PXD101), LAQ824, trichostatin A and panobinostat (LBH589); the benzamides are selected from entinostat (MS-275), CI994 and mocetinostat (MGCD0103); the cyclic tetrapeptide is trapoxin B); and the aliphatic acid compounds may be phenylbutyrate or valproic acid. 
     
     
         7 . The method of  claim 1 , wherein the vaccine is a viral vaccine that expresses the antigen. 
     
     
         8 . The method of  claim 1 , wherein the viral vaccine is an oncolytic virus. 
     
     
         9 . The method of  claim 8 , wherein the oncolytic virus is selected from the group consisting of rhabdoviruses, measles, vaccinia, herpes, myxoma, parvoviral, Newcastle disease, adenovirus and semliki forest virus. 
     
     
         10 . The method of  claim 8 , wherein the oncolytic virus is a vesiculovirus selected from the group consisting of vesicular stomatitis virus (VSV), Maraba virus, Ephemerovirus, Cytorhabdovirus, Nucleorhabdovirus and Lyssavirus virus. 
     
     
         11 . The method of  claim 1 , wherein the vaccine induces expression of type I interferon. 
     
     
         12 . The method of  claim 1 , wherein the vaccine is an antigen-presenting B-cell. 
     
     
         13 . The method of  claim 1 , wherein the vaccine is administered hi combination with an agent that induces expression of type I interferon. 
     
     
         14 . A composition comprising a vaccine and a histone deacetylase inhibitor. 
     
     
         15 . The composition of  claim 14 , wherein the vaccine is a viral vaccine. 
     
     
         16 . The composition of  claim 14 , wherein the vaccine induces type I interferon. 
     
     
         17 . The composition of  claim 14 , wherein the histone deacetylase inhibitor is selected from the group consisting of hydroxamic, benzamides, cyclic tetrapeptides, depsipeptides, electrophilic ketones, and aliphatic acid compounds. 
     
     
         18 . The composition of  claim 17 , wherein the hydroxamic acids are selected from vorinostat (SAHA), belinostat (PXD101), LAQ824, trichostatin A and panobinostat (LBH589); the benzamides are selected from entinostat (MS-275), CI994 and mocetinostat (MGCD0103); the cyclic tetrapeptide is trapoxin B); and the aliphatic acid compounds may be phenylbutyrate or valproic acid. 
     
     
         19 . The composition of  claim 14 , additionally comprising an agent that induces expression of type I interferon. 
     
     
         20 . The composition of  claim 19 , wherein the agent is selected from the group consisting of a toll-like receptor ligand, imiquimod, polyinosine-polycytidylic acid (polyI:C), CpG ODN, imidazoquinoline, monophosphoryl lipid A, flagellin, FimH and N-glycolyted muramyldipeptide

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.